Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.
Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, de Greef R, Chatterjee M, Kondic AG, Stone JA, Booth BP, Keegan P, Rahman A, Wang Y. Li H, et al. Among authors: de greef r. J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):403-414. doi: 10.1007/s10928-017-9528-y. Epub 2017 Jun 1. J Pharmacokinet Pharmacodyn. 2017. PMID: 28573468
Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial.
Elassaiss-Schaap J, Rossenu S, Lindauer A, Kang SP, de Greef R, Sachs JR, de Alwis DP. Elassaiss-Schaap J, et al. Among authors: de greef r, de alwis dp. CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):21-28. doi: 10.1002/psp4.12132. Epub 2016 Nov 8. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 27863143 Free PMC article.
Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.
Lindauer A, Valiathan CR, Mehta K, Sriram V, de Greef R, Elassaiss-Schaap J, de Alwis DP. Lindauer A, et al. Among authors: de greef r, de alwis dp. CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):11-20. doi: 10.1002/psp4.12130. Epub 2016 Nov 8. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 27863176 Free PMC article.
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, Elassaiss-Schaap J, Kondic A, Stone JA. Ahamadi M, et al. Among authors: de greef r, de alwis dp. CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):49-57. doi: 10.1002/psp4.12139. Epub 2016 Nov 14. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 27863186 Free PMC article.
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
Chatterjee MS, Elassaiss-Schaap J, Lindauer A, Turner DC, Sostelly A, Freshwater T, Mayawala K, Ahamadi M, Stone JA, de Greef R, Kondic AG, de Alwis DP. Chatterjee MS, et al. Among authors: de greef r, de alwis dp. CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):29-39. doi: 10.1002/psp4.12140. Epub 2016 Nov 29. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 27896938 Free PMC article.
Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, Stone JA. Freshwater T, et al. Among authors: de greef r, de alwis d. J Immunother Cancer. 2017 May 16;5:43. doi: 10.1186/s40425-017-0242-5. eCollection 2017. J Immunother Cancer. 2017. PMID: 28515943 Free PMC article.
Immunogenicity of pembrolizumab in patients with advanced tumors.
van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T. van Vugt MJH, et al. Among authors: de greef rhjmm. J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4. J Immunother Cancer. 2019. PMID: 31395089 Free PMC article.
54 results